$AMLX insider trading
Over the last 12 months, Amylyx Pharmaceuticals insiders reported 2 buys totaling $152K and 27 sales totaling $10.6M across SEC Form 4 filings. 3% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $152K 2 events
- Sold · 12m
- $10.6M 27 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 3% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Bedrosian Camille LChief Medical Officer · O | ▼ Sale | 10,028 | $32.4 | $325K | -3.5% | 2 tranches |
| Sep 10, 2026 | FRATES JAMES MChief Financial Officer · O | ▼ Sale | 10,810 | $32.36 | $350K | -4.4% | 2 tranches |
| Sep 10, 2026 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 9,536 | $32.46 | $310K | -4.8% | 2 tranches |
| Sep 10, 2026 | Klee Justin B.Co-Chief Executive Officer · O·D | ▼ Sale | 30,464 | $32.18 | $980K | -0.8% | 2 tranches |
| Sep 10, 2026 | Cohen Joshua BCo-Chief Executive Officer · O·D | ▼ Sale | 30,464 | $32.19 | $981K | -0.8% | 2 tranches |
| Jul 10, 2026 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 30,000 | $17.96 | $539K | -14.3% | plan · 2 tranches |
| May 21, 2026 | Firestone KarenD | ▲ Buy | 3,800 | $13.51 | $51K | +6% | — |
| Mar 2, 2026 | Klee Justin B.Co-Chief Executive Officer · O·D | ▼ Sale | 29,282 | $14.47 | $424K | -0.9% | — |
| Mar 2, 2026 | Cohen Joshua BCo-Chief Executive Officer · O·D | ▼ Sale | 29,282 | $14.48 | $424K | -0.9% | — |
| Mar 2, 2026 | Bedrosian Camille LChief Medical Officer · O | ▼ Sale | 6,461 | $14.58 | $94K | -3.7% | — |
| Mar 2, 2026 | FRATES JAMES MChief Financial Officer · O | ▼ Sale | 7,909 | $14.52 | $115K | -4.6% | — |
| Mar 2, 2026 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 6,844 | $14.52 | $99K | -4.8% | — |
| Feb 23, 2026 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 3,419 | $14.14 | $48K | -2.4% | — |
| Feb 2, 2026 | FRATES JAMES MChief Financial Officer · O | ▼ Sale | 3,557 | $14.65 | $52K | -2% | — |
| Feb 2, 2026 | Cohen Joshua BCo-Chief Executive Officer · O·D | ▼ Sale | 15,500 | $14.68 | $228K | -0.5% | — |
| Feb 2, 2026 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 3,448 | $14.65 | $51K | -2.3% | — |
| Feb 2, 2026 | Klee Justin B.Co-Chief Executive Officer · O·D | ▼ Sale | 15,500 | $14.68 | $228K | -0.5% | — |
| Jan 16, 2026 | Cohen Joshua BCo-Chief Executive Officer · O·D | ▼ Sale | 138,167 | $13.59 | $1.9M | -3.9% | 2 tranches |
| Jan 16, 2026 | Klee Justin B.Co-Chief Executive Officer · O·D | ▼ Sale | 138,188 | $13.59 | $1.9M | -3.9% | 2 tranches |
| Jan 6, 2026 | FRATES JAMES MChief Financial Officer · O | ▼ Sale | 3,326 | $11.11 | $37K | -1.8% | — |
| Jan 6, 2026 | Cohen Joshua BCo-Chief Executive Officer · O·D | ▼ Sale | 7,715 | $11.09 | $86K | -0.2% | — |
| Jan 6, 2026 | Klee Justin B.Co-Chief Executive Officer · O·D | ▼ Sale | 7,715 | $11.09 | $86K | -0.2% | — |
| Dec 23, 2025 | Firestone KarenD | ▲ Buy | 8,100 | $12.45 | $101K | +14.7% | — |
| Dec 1, 2025 | Bedrosian Camille LChief Medical Officer · O | ▼ Sale | 6,580 | $14.35 | $94K | -3.6% | — |
| Sep 30, 2025 | Klee Justin B.Co-Chief Executive Officer · O·D | ▼ Sale | 29,975 | $14.38 | $431K | -0.9% | 2 tranches |
| Sep 30, 2025 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 8,828 | $14.58 | $129K | -5.6% | — |
| Sep 30, 2025 | FRATES JAMES MChief Financial Officer · O | ▼ Sale | 10,558 | $14.65 | $155K | -3.6% | — |
| Sep 30, 2025 | Cohen Joshua BCo-Chief Executive Officer · O·D | ▼ Sale | 29,933 | $14.35 | $429K | -0.9% | 2 tranches |
| Sep 30, 2025 | Bedrosian Camille LChief Medical Officer · O | ▼ Sale | 12,039 | $14.58 | $176K | -6.2% | — |
| Aug 13, 2025 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 30,000 | $8.2 | $246K | -16% | plan · 2 tranches |
Every $AMLX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Amylyx Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AMLX feed.